CRISPR Therapeutics (CRSP) Competitors $58.94 -1.14 (-1.89%) As of 01:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRSP vs. ALLO, AXSM, BEAM, EDIT, KALA, MRNA, NTLA, VRTX, ILMN, and GMABShould you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), KALA BIO (KALA), Moderna (MRNA), Intellia Therapeutics (NTLA), Vertex Pharmaceuticals (VRTX), Illumina (ILMN), and Genmab A/S (GMAB). These companies are all part of the "med - biomed/gene" industry. CRISPR Therapeutics vs. Its Competitors Allogene Therapeutics Axsome Therapeutics Beam Therapeutics Editas Medicine KALA BIO Moderna Intellia Therapeutics Vertex Pharmaceuticals Illumina Genmab A/S Allogene Therapeutics (NASDAQ:ALLO) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk. Do insiders and institutionals believe in ALLO or CRSP? 83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, ALLO or CRSP? Allogene Therapeutics has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Which has preferable valuation and earnings, ALLO or CRSP? Allogene Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllogene TherapeuticsN/AN/A-$257.59M-$1.23-1.02CRISPR Therapeutics$37.31M136.00-$366.25M-$4.52-13.00 Is ALLO or CRSP more profitable? Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,023.64%. CRISPR Therapeutics' return on equity of -20.08% beat Allogene Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allogene TherapeuticsN/A -52.98% -41.28% CRISPR Therapeutics -1,023.64%-20.08%-17.13% Does the media refer more to ALLO or CRSP? In the previous week, CRISPR Therapeutics had 11 more articles in the media than Allogene Therapeutics. MarketBeat recorded 12 mentions for CRISPR Therapeutics and 1 mentions for Allogene Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.47 beat Allogene Therapeutics' score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ALLO or CRSP? Allogene Therapeutics currently has a consensus price target of $8.44, indicating a potential upside of 572.86%. CRISPR Therapeutics has a consensus price target of $71.75, indicating a potential upside of 22.12%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allogene Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90CRISPR Therapeutics 1 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.53 SummaryAllogene Therapeutics beats CRISPR Therapeutics on 8 of the 15 factors compared between the two stocks. Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRSP vs. The Competition Export to ExcelMetricCRISPR TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.06B$2.96B$5.58B$9.01BDividend YieldN/A2.44%5.25%4.03%P/E Ratio-12.9821.4727.5120.20Price / Sales136.00259.84415.84172.51Price / CashN/A41.8337.0657.97Price / Book2.607.788.085.61Net Income-$366.25M-$55.05M$3.17B$248.50M7 Day Performance12.66%5.38%3.57%4.92%1 Month Performance36.83%3.87%3.74%7.42%1 Year Performance5.75%5.72%33.78%21.48% CRISPR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRSPCRISPR Therapeutics2.4468 of 5 stars$58.76-2.2%$71.75+22.1%+9.2%$5.06B$37.31M-12.98460Analyst ForecastOptions VolumeGap UpALLOAllogene Therapeutics2.996 of 5 stars$1.15-2.5%$8.44+634.3%-47.4%$251.54M$20K-0.93310AXSMAxsome Therapeutics4.7359 of 5 stars$104.08+0.7%$172.33+65.6%+38.3%$5.12B$385.69M-18.04380BEAMBeam Therapeutics2.6711 of 5 stars$17.14+2.0%$48.75+184.4%-10.0%$1.72B$63.52M-3.72510Gap UpEDITEditas Medicine4.0586 of 5 stars$2.25-1.3%$4.70+108.9%-37.3%$188.35M$35.84M-0.74230KALAKALA BIO3.6828 of 5 stars$4.85+5.0%$13.50+178.4%-11.4%$31.29MN/A-0.5930News CoverageGap UpMRNAModerna4.4704 of 5 stars$27.53+1.4%$46.61+69.3%-71.7%$10.65B$3.24B-3.155,800Gap UpNTLAIntellia Therapeutics4.6354 of 5 stars$9.44-1.3%$33.37+253.5%-45.5%$977.80M$57.88M-1.80600VRTXVertex Pharmaceuticals4.4624 of 5 stars$444.51+0.7%$511.62+15.1%-1.4%$114.15B$11.02B-113.406,100Positive NewsAnalyst RevisionILMNIllumina4.8982 of 5 stars$95.17+0.4%$127.39+33.9%-8.7%$15.07B$4.37B-15.689,030Trending NewsAnalyst ForecastGMABGenmab A/S4.1764 of 5 stars$20.56+0.3%$37.60+82.9%-15.8%$13.18B$3.12B11.682,682News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Allogene Therapeutics Alternatives Axsome Therapeutics Alternatives Beam Therapeutics Alternatives Editas Medicine Alternatives KALA BIO Alternatives Moderna Alternatives Intellia Therapeutics Alternatives Vertex Pharmaceuticals Alternatives Illumina Alternatives Genmab A/S Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRSP) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRSP Stock Alerts